The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.

The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.

The present invention provides a high-purity arylsulfonic acid amine salt vinyl monomer which is an extremely industrially useful arylsulfonic acid monomer with excellent storage stability and amphiphilic solubility in both water and organic solvents, a simple and practical method for producing the same, a polyarylsulfonic acid amine salt which is a polymer thereof, and a method for producing the same. In the arylsulfonic acid amine salt vinyl monomer, a tertiary amine having 2 or 3 different substituents that each have 1 to 7 carbon atoms and also containing at least one or more of tertiary carbon or quaternary carbon or cyclic skeleton in the structure is applied to an amine moiety thereof, and in addition, a polyarylsulfonic acid amine salt having high purity in terms of sulfonation rate and polymerization conversion rate and a polymer thereof are used.

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The present disclosure provides borate or aluminate activators comprising cations having linear alkyl groups, catalyst systems comprising, and methods for polymerizing olefins using such activators. Specifically, the present disclosure provides activator compounds represented by Formula: [R.sup.1R.sup.2R.sup.3EH].sub.d.sup.+[M.sup.k+Q.sub.n].sup.d−, wherein: E is nitrogen or phosphorous; d is 1, 2 or 3; k is 1, 2, or 3; n is 1, 2, 3, 4, 5, or 6; n−k=d; R.sup.1 is C.sub.1-C.sub.20 linear alkyl group; each of R.sup.2 and R.sup.3 is a C.sub.1-C.sub.40 linear alkyl group, a meta- and/or para-substituted phenyl group, an alkoxy group, a silyl group, a halogen, or a halogen containing group, wherein R.sup.1+R.sup.2+R.sup.3≥15 carbon atoms; M is an element selected from group 13, typically B or Al; and each Q is independently a hydride, bridged or unbridged dialkylamido, halide, alkoxide, aryloxide, hydrocarbyl, substituted hydrocarbyl, halocarbyl, substituted halocarbyl, or halosubstituted-hydrocarbyl radical, provided that when Q is a fluorophenyl group, then R.sup.2 is not a C.sub.1-C.sub.40 linear alkyl group.

Methods of synthesizing transition metal dichalcogenide nanoparticles include forming a metal-amine complex, combining the metal-amine complex with a chalcogen source in at least one solvent to form a solution, heating the solution to a first temperature for a first period of time, and heating the solution to a second temperature that is higher than the first temperature for a second period of time.

Methods of synthesizing transition metal dichalcogenide nanoparticles include forming a metal-amine complex, combining the metal-amine complex with a chalcogen source in at least one solvent to form a solution, heating the solution to a first temperature for a first period of time, and heating the solution to a second temperature that is higher than the first temperature for a second period of time.

Provided is a hydrogenation catalyst for an amide compound, containing hydroxyapatite and platinum and vanadium that are fixed on the hydroxyapatite, 15 to 80% of the surface of the platinum being covered with vanadium. The hydrogenation catalyst can promote a reduction reaction in which an amide compound is converted into an amine compound, can be used under mild conditions, and has such durability that the catalyst can be repeatedly used while retaining a high activity.

Provided is a hydrogenation catalyst for an amide compound, containing hydroxyapatite and platinum and vanadium that are fixed on the hydroxyapatite, 15 to 80% of the surface of the platinum being covered with vanadium. The hydrogenation catalyst can promote a reduction reaction in which an amide compound is converted into an amine compound, can be used under mild conditions, and has such durability that the catalyst can be repeatedly used while retaining a high activity.